BWX Technologies (NYSE: BWXT) delivered a second quarter stronger than the headline numbers suggest. Non-GAAP EPS of $1.07 beat estimates by roughly 3%, and revenue of $901.6 million came in just a hair below the consensus $902.8 million.
The real story is inside the segments. Commercial Operations revenue surged 72% to $302.5 million. Segment operating income more than tripled to $24.3 million from $6.9 million a year ago.
The beat was broad-based. Government Operations revenue grew a modest 2% to $601.3 million, driven by naval propulsion and special materials, though lower advanced nuclear volumes provided an offset. Segment operating income dipped 3% to $105.7 million, a result of less favorable mix and the absence of positive contract adjustments that boosted the prior-year quarter. This is a normalizing effect, not a deterioration in the underlying business.
The torque is in the Commercial segment. The 72% revenue growth came from commercial nuclear components, field services, fuel handling, medical, and the contribution from Kinectrics. Operating income rose 254% on that revenue base. BWXT is spending to support that growth: SG&A investment increased, and capital expenditures in Commercial Operations rose 44% to $24.0 million. That spending signals confidence in the pipeline, not a cost control problem.
Management used the quarter to sharpen the portfolio. BWXT announced the sale of its medical business, a move that frees up capital and management attention for its core nuclear national defense and commercial nuclear power markets. It also closed the acquisition of Precision Components Group on July 1, establishing a U.S. manufacturing footprint for commercial nuclear components. These are strategic actions that align with the broader narrative: nuclear demand is broad and deep, and BWXT is positioning to capture it.
The guidance raise is the most telling signal. Full-year revenue guidance went to ~$3.8 billion from >$3.75 billion. Adjusted EBITDA guidance was raised to $662 million–$672 million from $650 million–$665 million. Non-GAAP EPS guidance went to $4.70–$4.80 from $4.60–$4.75. Free cash flow guidance was raised to $345 million–$360 million from $315 million–$330 million. The midpoint of the new FCF guidance implies a roughly 20% increase over the prior range. That's a meaningful upgrade, reflecting both strong first-half execution and the contribution from PCG.
Free cash flow in the quarter was $115 million, down 9% year over year, as higher capex for growth projects offset strong operating cash flow. This is a trade-off investors should welcome: the company is investing in capacity to meet demand already materializing. The $41.4 million in capex was up 27% from a year ago, and the full-year guidance implies a step-up in the back half.
A note on the beat: the GAAP EPS of $0.97 was well below the non-GAAP $1.07. The gap was driven by $6.2 million in restructuring and transformation costs, $3.7 million in acquisition-related costs, and $2.5 million in acquisition-related amortization. That's a lot of noise for a single quarter. Investors should watch whether these costs persist as the company integrates PCG and executes its strategic pivot.
What to watch next: the pace of Commercial segment growth and the margin trajectory as PCG contributions begin. The backlog is $8.4 billion, up 40% from a year ago, with Government Operations backlog at $6.8 billion. That provides multi-year visibility. The question is whether Commercial margins can sustain their improvement as the mix shifts toward higher-value components and services. The guidance raise suggests management believes they can.